Estimated Glomerular Filtration Rate Slope as an Endpoint in Cardiovascular Trials.
Curr Heart Fail Rep
; 21(4): 407-416, 2024 Aug.
Article
in En
| MEDLINE
| ID: mdl-38795231
ABSTRACT
PURPOSE OF REVIEW End stage kidney disease can be a slow process and it may be challenging to achieve required follow-up for sufficient events. Therefore, a surrogate kidney endpoint, such as estimated glomerular filtration rate (eGFR) slope maybe attractive to assess the kidney in cardiovascular trials, especially heart failure (HF). RECENT FINDINGS:
eGFR slope can generate informative results in a shorter follow-up period, has decreased risk of type-2 error, and is less sensitive to eGFR shifts compared with other surrogate kidney endpoints (eGFR decline≥40% or doubling creatinine). However, eGFR slope has its limitations with acute effects, heterogeneity in slope calculation/reporting, and deviations from linearity. eGFR slope is a kidney endpoint which may be well-suited for HF trials. Cross-collaborated guideline recommendations are needed to optimize the use of eGFR slope as a kidney endpoint in patients with HF.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Clinical Trials as Topic
/
Glomerular Filtration Rate
/
Heart Failure
Limits:
Humans
Language:
En
Journal:
Curr Heart Fail Rep
Journal subject:
CARDIOLOGIA
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: